Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture

doi:10.22608/APO.2017466

Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture

Research output: Contribution to Journal › Review article › peer-review

Abstract

The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevaci-zumab as a preoperative, adjuvant therapy before vitrectomy for prolif-erative diabetic retinopathy.

Original language	English (US)
Pages (from-to)	36-39
Number of pages	4
Journal	Asia-Pacific Journal of Ophthalmology
Volume	7
Issue number	1
DOIs	https://doi.org/10.22608/APO.2017466
State	Published - Jan 1 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Ophthalmology

Access to Document

10.22608/APO.2017466

Cite this

@article{d24741c36be9491ca60e1df919984956,

title = "Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture",

abstract = "The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevaci-zumab as a preoperative, adjuvant therapy before vitrectomy for prolif-erative diabetic retinopathy.",

author = "Arevalo, \{J. Fernando\} and Liu, \{T. Y.Alvin\} and L. Wu and Lasave, \{A. F.\} and M. Farah and M. Maia and Penha, \{F. M.\} and Rodrigues, \{E. B.\} and V. Morales-Canton and J. Fromow-Guerra and Guerrero-Naranjo, \{J. L.\} and J. Dalma-Weiszhausz and R. Velez-Montoya and H. Quiroz-Mercado and Rodriguez, \{F. J.\} and Gomez, \{F. E.\} and Brieke, \{A. C.\} and A. Goveto and Berrocal, \{M. H.\} and V. Cruz-Villegas and F. Graue-Wiechers and D. Lozano-Rechy and E. Fulda-Graue and Roca, \{J. A.\} and A. Hern{\'a}ndez and Saravia, \{M. J.\} and A. Schlaen and J. Rojas and M. Ingolotti and M. Avila and L. Carla and J. Cardillo and R. Jorge and C. Carpentier and J. Verdaguer and Verdaguer, \{J. I.\} and G. Sep{\'u}lveda and A. Alezzandrini and B. Garcia and M. Zas and R. Gallego-Pinazo and M. Diaz-Llopis and R. Dolz-Marco and M. Figueroa and I. Contreras and D. Ruiz-Casas",

note = "Publisher Copyright: Copyright {\textcopyright} 2017 by Asia Pacific Academy of Ophthalmology.",

year = "2018",

month = jan,

day = "1",

doi = "10.22608/APO.2017466",

language = "English (US)",

volume = "7",

pages = "36--39",

journal = "Asia-Pacific Journal of Ophthalmology",

issn = "2162-0989",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture

AU - Arevalo, J. Fernando

AU - Liu, T. Y.Alvin

AU - Wu, L.

AU - Lasave, A. F.

AU - Farah, M.

AU - Maia, M.

AU - Penha, F. M.

AU - Rodrigues, E. B.

AU - Morales-Canton, V.

AU - Fromow-Guerra, J.

AU - Guerrero-Naranjo, J. L.

AU - Dalma-Weiszhausz, J.

AU - Velez-Montoya, R.

AU - Quiroz-Mercado, H.

AU - Rodriguez, F. J.

AU - Gomez, F. E.

AU - Brieke, A. C.

AU - Goveto, A.

AU - Berrocal, M. H.

AU - Cruz-Villegas, V.

AU - Graue-Wiechers, F.

AU - Lozano-Rechy, D.

AU - Fulda-Graue, E.

AU - Roca, J. A.

AU - Hernández, A.

AU - Saravia, M. J.

AU - Schlaen, A.

AU - Rojas, J.

AU - Ingolotti, M.

AU - Avila, M.

AU - Carla, L.

AU - Cardillo, J.

AU - Jorge, R.

AU - Carpentier, C.

AU - Verdaguer, J.

AU - Verdaguer, J. I.

AU - Sepúlveda, G.

AU - Alezzandrini, A.

AU - Garcia, B.

AU - Zas, M.

AU - Gallego-Pinazo, R.

AU - Diaz-Llopis, M.

AU - Dolz-Marco, R.

AU - Figueroa, M.

AU - Contreras, I.

AU - Ruiz-Casas, D.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevaci-zumab as a preoperative, adjuvant therapy before vitrectomy for prolif-erative diabetic retinopathy.

AB - The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevaci-zumab as a preoperative, adjuvant therapy before vitrectomy for prolif-erative diabetic retinopathy.

UR - https://www.scopus.com/pages/publications/85044056870

UR - https://www.scopus.com/pages/publications/85044056870#tab=citedBy

U2 - 10.22608/APO.2017466

DO - 10.22608/APO.2017466

M3 - Review article

C2 - 29280367

AN - SCOPUS:85044056870

SN - 2162-0989

VL - 7

SP - 36

EP - 39

JO - Asia-Pacific Journal of Ophthalmology

JF - Asia-Pacific Journal of Ophthalmology

IS - 1

ER -

Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this